In the study of Sadahiro et al.., AXL inhibition using bemcentinib in murine glioblastoma resulted in decreased PD-L1 and increased PD-L2 (CD273, PDCD1LG2 or B7-DC) expression [94]. The gene discussed is AXL; the disease is glioblastoma.